[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Page 34027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-11828]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Anti-Mesothelin 
Antibodies Useful for Immunological Assays

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Patent Application No. 60/681,104, filed May 12, 2005, entitled ``Anti-
Mesothelin Antibodies Useful For Immunological Assays'' [E-015-2005/0-
US-01] and PCT Application No. PCT/US2006/018502, filed May 11, 2006, 
entitled ``Anti-Mesothelin Antibodies Useful For Immunological Assays'' 
[E-015-2005/0-PCT-02] to Cambridge Antibody Technology, Ltd., which has 
offices in Cambridge, United Kingdom. The patent rights in these 
inventions have been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of the SSIP immunoconjugate 
and variants thereof for the treatment of mesothelin expressing 
cancers.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
August 20, 2007 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jesse S. Kindra, J.D., M.S., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5559; Facsimile: (301) 402-0220; E-
mail: [email protected].

SUPPLEMENTARY INFORMATION: This technology relates to anti-mesothelin 
antibodies with a particularly high affinity for mesothelin and the 
ability to be used in immunological assays for detecting the presence 
of mesothelin in biological samples. The anti-mesothelin antibodies are 
well-suited for the diagnosis and treatment of cancers of the ovary, 
stomach, squamous cells, mesotheliomas and other malignant cells 
expressing mesothelin.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: June 11, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer,Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-11828 Filed 6-19-07; 8:45 am]
BILLING CODE 4140-01-P